Search Results - "OLOFSSON, Bertil"

Albuminuria in chronic heart failure: prevalence and prognostic importance by Jackson, Colette E, MB ChB, Solomon, Scott D, MD, Gerstein, Hertzel C, Prof, Zetterstrand, Sofia, PhD, Olofsson, Bertil, PhD, Michelson, Eric L, Prof, Granger, Christopher B, Prof, Swedberg, Karl, Prof, Pfeffer, Marc A, Prof, Yusuf, Salim, Prof, McMurray, John JV, Prof

“…Summary Background Increased excretion of albumin in urine might be a marker of the various pathophysiological changes that arise in patients with heart…”
Get full text

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure by Desai, Akshay S., MD, Swedberg, Karl, MD, PhD, FACC, McMurray, John J.V., MD, FACC, Granger, Christopher B., MD, FACC, Yusuf, Salim, MD, Dphil, FACC, Young, James B., MD, FACC, Dunlap, Mark E., MD, FACC, Solomon, Scott D., MD, Hainer, James W., MD, Olofsson, Bertil, PhD, Michelson, Eric L., MD, FACC, Pfeffer, Marc A., MD, PhD, FACC

“…Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program Akshay S. Desai, Karl Swedberg, John J. V. McMurray,…”
Get full text

Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design by Swedberg, Karl, Pfeffer, Marc, Granger, Chris, Held, Peter, Mcmurray, John, Ohlin, Gunilla, Olofsson, Bertil, Östergren, Jan, Yusuf, Salim

“…Background: Chronic heart failure (CHF) is an increasing burden to health care. Pharmacological treatment with angiotensin-converting enzyme (ACE) inhibitors…”
Get full text

Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program by Meredith, Peter A., PhD, Östergren, Jan, MD, Anand, Inder, MD, Puu, Margareta, PhD, Solomon, Scott D., MD, Michelson, Eric L., MD, Olofsson, Bertil, PhD, Granger, Christopher B., MD, Yusuf, Salim, MB, BS, DPhil, Swedberg, Karl, MD, PhD, Pfeffer, Marc A., MD, PhD, McMurray, John J.V., MD

“…Objectives This study sought to investigate the efficacy and tolerability of candesartan, according to baseline blood pressure (BP), in the 4,576 patients with…”
Get full text

The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients by Trenkwalder, Peter, Elmfeldt, Dag, Hofman, Albert, Lithell, Hans, Olofsson, Bertil, Papademetriou, Vasilios, Skoog, Ingmar, Zanchetti, Alberto

“…The Study on COgnition and Prognosis in the Elderly (SCOPE) assessed the effect of candesartan on cardiovascular outcomes in elderly patients with mild to…”
Get more information

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial by McMurray, John J.V., Young, James B., Dunlap, Mark E., Granger, Christopher B., Hainer, James, Michelson, Eric L., Earle, Steven, Olofsson, Bertil, Östergren, Jan, Yusuf, Salim, Swedberg, Karl, Pfeffer, Marc A.

“…Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is…”
Get full text

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial by Lithell, Hans, Hansson, Lennart, Skoog, Ingmar, Elmfeldt, Dag, Hofman, Albert, Olofsson, Bertil, Trenkwalder, Peter, Zanchetti, Alberto

“…BACKGROUNDThe prognostic benefits of blood pressure lowering treatment in elderly hypertensive patients were established more than a decade ago, but are less…”
Get full text

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial by Yusuf, Salim, Pfeffer, Marc A, Swedberg, Karl, Granger, Christopher B, Held, Peter, McMurray, John JV, Michelson, Eric L, Olofsson, Bertil, Östergren, Jan

“…Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed…”
Get full text

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme by Pfeffer, Marc A, Swedberg, Karl, Granger, Christopher B, Held, Peter, McMurray, John JV, Michelson, Eric L, Olofsson, Bertil, Östergren, Jan, Yusuf, Salim

“…Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of…”
Get full text

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial by McMurray, John JV, Östergren, Jan, Swedberg, Karl, Granger, Christopher B, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Yusuf, Salim, Pfeffer, Marc A

“…Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when…”
Get full text

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial by Granger, Christopher B, McMurray, John JV, Yusuf, Salim, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Östergren, Jan, Pfeffer, Marc A, Swedberg, Karl

“…Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however,…”
Get full text

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial by Granger, Bradi B, Swedberg, Karl, Ekman, Inger, Granger, Christopher B, Olofsson, Bertil, McMurray, John JV, Yusuf, Salim, Michelson, Eric L, Pfeffer, Marc A

“…Chronic heart failure (CHF) is an important cause of hospital admission and death. Poor adherence to medication is common in some chronic illnesses and might…”
Get full text

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with Isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE) by PAPADEMETRIOU, Vasilios, FARSANG, Csaba, ELMFELDT, Dag, HOFMAN, Albert, LITHELL, Hans, OLOFSSON, Bertil, SKOOG, Ingmar, TRENKWALDER, Peter, ZANCHETTI, Alberto

“…The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly…”
Get full text

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program by Ducharme, Anique, Swedberg, Karl, Pfeffer, Marc A., Cohen-Solal, Alain, Granger, Christopher B., Maggioni, Aldo P., Michelson, Eric L., McMurray, John J.V., Olsson, Lars, Rouleau, Jean L., Young, James B., Olofsson, Bertil, Puu, Margareta, Yusuf, Salim

“…Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF). Experimental and small patient studies have demonstrated that blocking the…”
Get full text

Incidence and predictors of hyperkalemia in patients with heart failure : An analysis of the CHARM program by DESAI, Akshay S, SWEDBERG, Karl, MICHELSON, Eric L, PFEFFER, Marc A, MCMURRAY, John J. V, GRANGER, Christopher B, YUSUF, Salim, YOUNG, James B, DUNLAP, Mark E, SOLOMON, Scott D, HAINER, James W, OLOFSSON, Bertil

“…We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients. When used in optimal doses to treat patients with…”
Get full text

Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) by Skoog, Ingmar, Lithell, Hans, Hansson, Lennart, Elmfeldt, Dag, Hofman, Albert, Olofsson, Bertil, Trenkwalder, Peter, Zanchetti, Alberto

Get full text

Mortality and morbidity reduction with candesartan in patients with chronic heart failure and Left ventricular systolic dysfunction : Results of the CHARM low-left ventricular ejection fraction trials by YOUNG, James B, DUNLAP, Mark E, MCMURRAY, John J. V, MICHELSON, Eric L, OLOFSSON, Bertil, OSTERGREN, Jan, HELD, Peter, SOLOMON, Scott D, YUSUF, Salim, SWEDBERG, Karl, PFEFFER, Marc A, PROBSTFIELD, Jeffrey L, COHEN-SOLAL, Alain, DIETZ, Rainer, GRANGER, Christopher B, HRADEC, Jaromir, KUCH, Jerzy, MCKELVIE, Robert S

“…Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for…”
Get full text

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure by YUSUF, Salim, OSTERGREN, Jan B, GERSTEIN, Hertzel C, PFEFFER, Marc A, SWEDBERG, Karl, GRANGER, Christopher B, OLOFSSON, Bertil, PROBSTFIELD, Jeffrey, MCMURRAY, John V

“…Diabetes is a risk factor for heart failure, and both conditions are increasing. Identifying treatments that prevent both conditions will be clinically…”
Get full text

Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) by Skoog, Ingmar, Lithell, Hans, Hansson, Lennart, Elmfeldt, Dag, Hofman, Albert, Olofsson, Bertil, Trenkwalder, Peter, Zanchetti, Alberto

“…We examined whether cognitive function at baseline affected cognitive and cardiovascular outcomes in the Study on COgnition and Prognosis in the Elderly…”
Get full text

Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives by Dimenäs, E S, Wiklund, I K, Dahlöf, C G, Lindvall, K G, Olofsson, B K, De Faire, U H

“…In this study, previously untreated subjects were randomly recruited from a blood pressure screening programme. After repeated measurement of blood pressure…”
Get more information